Clinical trial
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto…
NCT00090493 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00090493 |
|---|---|
| Title | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma |
| Official title | UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma |
| Lead sponsor | University of Arkansas, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological |
| Interventions | MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY |
| Enrollment | 4 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | May 1, 2012 |
| First posted | Aug 31, 2004 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: